Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Three therapies, Teva’s Huntexil, Auspex’s SD-809 and Raptor’s Procysbi, will likely receive regulatory approval for Huntington’s disease in the United States and the EU5 markets... Learn More
Join us live on September 17, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Come join us for an exciting one-day seminar.
Hear in-depth analysis of hot topics and trends concerning global oncology while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
September 10, 2014
Expected Launch of First Disease-Modifying Therapies Through 2023 Will Revolutionize Treatment of Duchenne Muscular Dystrophy
September 8, 2014
The Psoriatic Arthritis Market Will Reach More than $3.5 Billion in 2023, Owing to Continued Uptake of Biologics and Penetration of Premium-Priced Orals
September 3, 2014
Exchange Plans, Medicaid Expansion Will Boost Access to Drugs for Major Depression, Bipolar Disorder and Schizophrenia
August 28, 2014
The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies
Type 2 Diabetes - 2014
Last Updated 12 September 2014 The type 2 diabetes therapy market will rapidly expand over our 2013-2023... Read More
Market Access Opportunities and Obstacles for Type 2 Diabetes in South Korea and Taiwan: Physician and Payer Insights
South Korea and Taiwan have the most advanced healthcare systems among Asian countries, and both operate a universal... Read More
Crohn’s Disease and Ulcerative Colitis: U.S. Physician and Payer Perspectives on Established and Recently Launched Biologics, Emerging Novel Agents and Biosimilars
Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that... Read More